Search PubMed⌕ Search

PubMed · 15651484

[Augmentation enterocystoplasty].

Abstract

Augmentation enterocystoplasty refers to a technique that consists in removing a bowel segment in order to suture it onto the bladder. This technique is indicated in case of reduced bladder capacity and/or compliance, in case of failure of conservative treatments. The goal is to improve the patient's urination comfort, but above all to ensure long-term protection of the upper urinary tract. All bowel segments may be utilized but the ileum is the segment of choice. The selected digestive segment must be detubulized in order to better decrease its peristaltic contractions and obtain low-pressure urine storage. Bi-valving the bladder while preserving the detrusor usually performs augmentation enterocystoplasty. However, in case of very fibrous and thickened detrusor, a supra-trigonal cystectomy should be considered. The digestive segment is removed and detubulized, then it is sutured on to the bladder as a patch at the incision level. Following such surgery, over 90% of the patients report significantly improved quality of life. Nocturnal bladder competence is obtained in more than 90% of the patients, while 91 to 100% report diurnal bladder competence. Long-term complications may be observed, such as chronic infections with asymptomatic bacteruria (70% of the cases) not necessitating any treatment. Within the two first years, there is a 10% to 15% risk for stone formation following intestinal mucus development. Enterocystoplasty perforation may occur at a frequency estimated to range from 5 to 13%, which is a very serious and life-threatening complication. Similarly, a risk of enterocystoplasty cancer may be observed after five to ten years, in 1% of the cases.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J Rigaud, L Le Normand. 2004. [Augmentation enterocystoplasty].. https://doi.org/10.1016/j.anuro.2004.08.001

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Impact of pre-operative MRI-measured membranous urethral length on urinary continence after radical cystectomy and orthotopic substitution: clinical and urodynamic evaluation.

PURPOSE: We aimed to determine the impact of membranous urethral length as measured by preoperative magnetic resonance imaging (MRI) upon continence following radical cystectomy and orthotopic substitution. MATERIALS AND METHODS: A total of 40 male patients (mean age 55.7 +/- 7 years) were subjected to radical cystectomy and orthotopic ileal substitution for bladder cancer. Membranous urethral length was measured by preoperative MRI utilizing coronal oblique high resolution T2 weighted images. In all evaluable patients, day and night continence statuses as well as time to stable continence were recorded. Urodynamic assessment included medium fill pouchometry and urethral pressure profilometry. RESULTS: Of all patients 10 were non-evaluable. Mean follow-up period was 8.1 +/- 1.9 months. All the evaluable patients were continent by daytime. On the other hand, 13 were continent by night (43.3%), 13 showed occasional enuresis (43.3%) and 4 were nightly enuretic (13.4%). Mean membranous urethral lengths were 14 +/- 1.9, 13.8 +/- 1.9 and 12.8 +/- 1.7 mm in the three groups, respectively (P = 0.51). Mean time to reach stable postoperative daytime continence was 5.4 +/- 4.6 whilst it was 12.5 +/- 7.4 weeks for nighttime continence. There was no significant correlation between preoperative membranous urethral length and time to stable day or night continence (R = -0.11, -0.08, respectively). Moreover, such correlation was not observed with postoperative urethral pressure profilometry parameters including maximum urethral pressure, maximum urethral closure pressure or functional urethral length (R = -0.33, -0.38, -0.16, respectively). CONCLUSION: Preoperative MRI-measured membranous urethral length has no value for judgment of postoperative continence status following radical cystectomy and ileal bladder substitution.

Cystectomy↗

Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments.

Bladder cancer is a heterogeneous disease. Non-muscle-invasive bladder cancer embraces a spectrum of tumors with varying degrees of clinical behavior. Transurethral resection remains the surgical mainstay for the treatment of non-muscle-invasive bladder cancer. In an attempt to decrease the recurrence or progression rate, intravesical chemotherapy or immunotherapy is also used. Radical cystectomy with bilateral pelvic lymph node dissection remains the gold standard for treating muscle-invasive bladder cancer. Over the last decade, the orthotopic neobladder has gained widespread popularity as the preferred mode of urinary diversion in both males and females with similar oncologic and functional outcomes. Well-designed trials with effective chemotherapy have shown a beneficial role for neoadjuvant chemotherapy.

Cystectomy↗